Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/de/publications/11209-a-randomised-phase-ii-study-of-osimertinib-and-bevacizumab-versus-osimertinib-alone-as-second-line-targeted-treatment-in-advanced-nsclc-with-confirmed-egfr-and-acquired-t790m-mutations-the-european-thoracic-oncology-platform-etop-10-16-booster-trial/authors?page=1